RENMICE Trademark

Trademark Overview

On Wednesday, October 20, 2021, a trademark application was filed for RENMICE with the United States Patent and Trademark Office. The USPTO has given the RENMICE trademark a serial number of 79329198. The federal status of this trademark filing is REGISTERED as of Tuesday, September 3, 2024. This trademark is owned by Biocytogen Pharmaceuticals (Beijing) Co., Ltd.. The RENMICE trademark is filed in the Pharmaceutical Products category with the following description:

Medicines for human purposes for the treatment of tumors, infectious diseases, inflammation and autoimmune diseases; diagnostic preparations for medical and veterinary purposes; biological preparations for medical purposes for the treatment of tumors, infectious diseases, inflammation and autoimmune diseases; active pharmaceutical ingredients, namely, antibodies for the treatment of human and animal diseases; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of cancer; biochemical medicines for the treatment of tumors, infectious diseases, inflammation and autoimmune diseases; vaccines; dietetic preparations adapted for medical use; medicines for veterinary purposes for the treatment of tumors, infectious diseases, inflammation and autoimmune diseases
renmice

General Information

Serial Number79329198
Word MarkRENMICE
Filing DateWednesday, October 20, 2021
Status700 - REGISTERED
Status DateTuesday, September 3, 2024
Registration Number7490473
Registration DateTuesday, September 3, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 18, 2024

Trademark Statements

Goods and ServicesMedicines for human purposes for the treatment of tumors, infectious diseases, inflammation and autoimmune diseases; diagnostic preparations for medical and veterinary purposes; biological preparations for medical purposes for the treatment of tumors, infectious diseases, inflammation and autoimmune diseases; active pharmaceutical ingredients, namely, antibodies for the treatment of human and animal diseases; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of cancer; biochemical medicines for the treatment of tumors, infectious diseases, inflammation and autoimmune diseases; vaccines; dietetic preparations adapted for medical use; medicines for veterinary purposes for the treatment of tumors, infectious diseases, inflammation and autoimmune diseases
Pseudo MarkREN MICE

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, January 3, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBiocytogen Pharmaceuticals (Beijing) Co., Ltd.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressCN
Party NameBiocytogen Pharmaceuticals (Beijing) Co., Ltd.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCN
Party NameBiocytogen Pharmaceuticals (Beijing) Co., Ltd.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCN

Trademark Events

Event DateEvent Description
Thursday, December 23, 2021SN ASSIGNED FOR SECT 66A APPL FROM IB
Monday, January 3, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, March 1, 2023TEAS REQUEST TO DIVIDE RECEIVED
Friday, January 7, 2022APPLICATION FILING RECEIPT MAILED
Wednesday, July 27, 2022ASSIGNED TO EXAMINER
Sunday, July 31, 2022NON-FINAL ACTION WRITTEN
Monday, August 1, 2022NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Saturday, September 3, 2022REFUSAL PROCESSED BY MPU
Saturday, September 3, 2022NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Tuesday, September 27, 2022REFUSAL PROCESSED BY IB
Wednesday, March 1, 2023DIVISIONAL REQUEST RECEIVED
Wednesday, March 1, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, March 1, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, March 1, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, March 23, 2023DIVISIONAL PROCESSING COMPLETE
Thursday, March 23, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, March 24, 2023LETTER OF SUSPENSION E-MAILED
Friday, March 24, 2023SUSPENSION LETTER WRITTEN
Friday, March 24, 2023NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Tuesday, March 28, 2023NEW REPRESENTATIVE AT IB RECEIVED
Wednesday, May 24, 2023NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Wednesday, May 24, 2023NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Monday, June 12, 2023NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Thursday, September 21, 2023REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Monday, March 25, 2024SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Tuesday, April 2, 2024PRIORITY ACTION WRITTEN
Tuesday, April 2, 2024PRIORITY ACTION E-MAILED
Tuesday, April 2, 2024NOTIFICATION OF PRIORITY ACTION E-MAILED
Wednesday, May 15, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 29, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 11, 2024NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Tuesday, June 11, 2024NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Tuesday, September 3, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, June 18, 2024PUBLISHED FOR OPPOSITION
Tuesday, June 18, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Saturday, July 20, 2024NOTIFICATION PROCESSED BY IB
Saturday, February 15, 2025GENERIC MADRID TRANSACTION CREATED
Tuesday, September 3, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, December 3, 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Saturday, February 15, 2025GENERIC MADRID TRANSACTION SENT TO IB
Saturday, April 26, 2025Further Decision Processed by IB

Related Keywords

renmice diseases treatment preparations inflammation autoimmune purposes infectious tumors medicines pharmaceutical